文献速递产科母胎医学

产前糖皮质激素:预期获益与潜在风险的更新评估

Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks.
PubMed 文献 · Am J Obstet Gynecol · 2023-09-19

产前糖皮质激素是24至34周有早产风险孕妇的标准治疗,在高资源环境中靶向使用获益大、风险小。近期研究将其应用扩展至围存活期、晚期早产及足月剖宫产,应用孕周达22至39+6周。总体疗效高度可变,治疗方案多属任意,剂量超药理效应,获益-风险平衡随孕周显著不同,长期风险及与儿童精神疾病、新生儿感染的关联值得关注。

要点

  • 产前糖皮质激素是24至34周可能早产孕妇的标准治疗,高资源环境靶向使用获益大、风险小。
  • 近期应用扩展至围存活期、晚期早产及足月剖宫产,孕周范围达22至39+6周。
  • 总体疗效高度可变,方案多属任意,剂量超药理效应,获益-风险平衡随孕周显著不同。

核心结论

  • 产前糖皮质激素总体疗效高度可变,治疗方案多属任意,剂量超药理效应,获益-风险平衡随孕周显著且差异化改变。
  • 少数随访研究显示长期风险总体良性,但多项大型人群回顾性研究提示产前糖皮质激素使用与儿童精神疾病及新生儿感染存在关联,值得紧急关注。
  • 当代重要方向包括基于药代动力学与药效学优化方案、更好靶向使用,并明确不同孕周及分娩情境下的获益与风险。

研究设计与样本

  • 本文为更新评估,聚焦产前糖皮质激素的预期获益与潜在风险。
  • 所依据的随机对照数据绝大多数来自以高资源、白人为主的人群。

主要发现

  • 对24至34周可能分娩孕妇,产前糖皮质激素在高资源环境靶向使用时获益大、风险小。
  • 产前糖皮质激素现已应用于估计孕龄22至39+6周。
  • 总体疗效高度可变,包括早产风险被准确评估时。
  • 所用治疗方案多属任意,剂量超药理效应,获益-风险平衡随孕周显著且差异化改变。
  • 多项大型人群回顾性研究发现产前糖皮质激素使用与儿童精神疾病及新生儿感染存在关联。

关键数值与推荐

  • 对24至34周可能分娩孕妇,产前糖皮质激素为高资源环境下的标准治疗。
  • 产前糖皮质激素应用孕周范围为22至39+6周。

临床怎么用

  • 对24至34周可能分娩孕妇,在高资源环境中靶向使用产前糖皮质激素作为标准治疗。
  • 需基于药物药代动力学与药效学优化产前糖皮质激素方案,并更好靶向使用。
  • 需向患者明确说明不同孕周及不同分娩情境下产前糖皮质激素的潜在获益与风险。

局限性

  • 绝大多数随机对照数据来自以高资源、白人为主的人群。
  • 总体疗效高度可变,包括早产风险被准确评估时。
  • 治疗方案多属任意,剂量超药理效应。
  • 获益-风险平衡随孕周显著且差异化改变。
  • 需紧急关注产前糖皮质激素与儿童精神疾病及新生儿感染关联的回顾性研究结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Antenatal steroid therapy is increasingly central to the obstetrical management of women at imminent risk of preterm birth. For women likely to deliver between 24 and 34 weeks' gestation, antenatal steroid therapy is the standard of care, conferring sizable benefits and few risks in high-resource environments when appropriately targeted. Recent studies have focused on antenatal steroid use in periviable and late preterm populations, and in term cesarean deliveries. As a result, antenatal steroid therapy has now been applied from 22 to 39+6 weeks of estimated gestational age. There is also an increased appreciation that the vast majority of randomized control data informing the use of antenatal steroids are derived from predominantly high-resource, White populations. Accordingly, a sizable amount of work has recently been undertaken to test how to safely use antenatal steroids in low- and middle-resource environments, wherein the often high rates of preterm birth make these low-cost, easily administered interventions an attractive proposition. It is likely underappreciated by the obstetrical and neonatal communities that the overall efficacy of antenatal steroid therapy is highly variable (including when preterm risk is accurately assessed), the treatment regimens used are largely arbitrary, dosing is suprapharmacologic for effect, and the benefit-risk balance is significantly and differentially modified by gestation. It is also very likely that the patients consenting to receive these treatments are similarly unaware of the complex balance of potential benefits and harms. Although a small number of follow-up studies present a generally benign picture of long-term antenatal steroid risk, several large, population-based retrospective studies have identified associations between antenatal steroid use, childhood mental disease, and newborn infections that warrant urgent attention. Of particular contemporary importance are emergent efforts to optimize antenatal steroid regimens on the basis of the pharmacokinetics and pharmacodynamics of the agents themselves, the need for better targeting of these potent drugs, and clear articulation of the potential benefits and harms of antenatal steroid use at differing stages of pregnancy and in different delivery contexts.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Jobe AH, Goldenberg RL, Kemp MW, et al. Antenatal corticosteroids: an updated assessment of anticipated benefits and potential risks. Am J Obstet Gynecol. 2023. PMID: 37734637. doi:10.1016/j.ajog.2023.09.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。